Sirolimus-Coated Balloon Angioplasty Superior for Infrainguinal Artery Disease

A major trial published in the New England Journal of Medicine demonstrates that sirolimus-coated balloon angioplasty effectively reduces the incidence of major adverse limb events in patients with infrainguinal artery disease. These findings from the SirPAD trial represent a significant shift in the endovascular management of peripheral arterial conditions worldwide. Given the high burden of peripheral artery disease in India, specifically among patients with diabetes, this evidence provides a vital upgrade to current treatment protocols.

The study enrolled 1,252 patients across multiple centers to compare clinical outcomes. Specifically, researchers randomly assigned participants to receive either a sirolimus-coated balloon or a standard uncoated balloon. They primarily aimed to evaluate the composite rate of unplanned major amputation or target lesion revascularization for critical limb ischemia within one year. Consequently, the results provide high-quality evidence for clinical decision-making in vascular interventions.

Advantages of Sirolimus-Coated Balloon Angioplasty

The sirolimus-coated group showed a significantly lower primary-outcome rate of 8.8% compared to 15.0% in the uncoated group. Additionally, the statistical analysis confirmed the superiority of the drug-coated platform with a significant p-value of 0.009. Therefore, this technology offers a robust solution for maintaining vessel patency. Moreover, the safety profile was very reassuring for practitioners. There were no significant differences in all-cause mortality between the two groups. As a result, clinicians can confidently adopt this technique without increased safety concerns.

In contrast to previous studies using different drugs, sirolimus acts as a cytostatic agent. It effectively inhibits neointimal hyperplasia after the initial procedure. Furthermore, this approach minimizes the need for repeated interventions. Similarly, it reduces the risk of limb loss in vulnerable patient populations. However, practitioners must ensure proper vessel preparation to optimize drug transfer. Overall, the trial reinforces the role of advanced balloon technologies in modern practice.

Frequently Asked Questions

What was the primary outcome of the SirPAD trial?

The primary outcome was a composite of unplanned major amputation or revascularization of the target lesion for critical limb ischemia within one year. The trial found that sirolimus-coated balloons reduced these events by nearly half compared to uncoated balloons.

How does a sirolimus-coated balloon work?

The balloon delivers sirolimus, an anti-proliferative drug, directly to the arterial wall during inflation. This drug prevents the overgrowth of cells that typically causes the vessel to narrow again after angioplasty.

Was there a difference in mortality in the trial?

No, the study reported no significant difference in death from any cause within one year between the sirolimus-coated and uncoated balloon groups, ensuring a high margin of safety.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Always seek the advice of a qualified healthcare provider for any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Barco S et al. Sirolimus-Coated Balloon Angioplasty for Infrainguinal Artery Disease. N Engl J Med. 2026 Mar 30. doi: 10.1056/NEJMoa2600360. PMID: 41911022.

American College of Cardiology. SirPAD: Sirolimus-Coated vs. Uncoated Balloons in Angioplasty For Infrainguinal Artery Disease. Late-Breaking Clinical Trial Session; 2026 Mar 30.